GlassScriptPhysician profile
Tabitha M Smith
NPI 1003112277
$8,539.21
in general payments reported to CMS, 2019-2025
43 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,288 · 2022: $1,243 · 2023: $1,515 · 2024: $1,647 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,909 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,909.36 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,045.99 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $908.31 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $704.58 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $672.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $433.79 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.56 | 2022-2025 | Caplyta |
| Corcept Therapeutics | $231.84 | 2021-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $215.30 | 2021-2025 | Trintellix |
| Lundbeck LLC | $212.77 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $206.24 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.69 | 2021-2025 | Xifaxan, Trulance |
| Mannkind Corporation | $193.01 | 2024-2025 | |
| Pfizer INC. | $182.81 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $156.94 | 2025 | Fanapt |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $155.82 | 2023-2025 | |
| Lilly USA, LLC | $153.88 | 2021-2025 | Mounjaro, Jardiance |
| Alkermes, INC. | $133.05 | 2024-2025 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $127.59 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $113.18 | 2021-2023 | Belsomra, Steglatro, Steglujan |
| Incyte Corporation | $99.00 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.76 | 2022 | |
| Antares Pharma, INC. | $88.33 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $85.26 | 2023-2025 | Cologuard Collection Kit |
| Revance Therapeutics, INC. | $52.49 | 2025 | Daxxify |
| Genentech USA, INC. | $42.41 | 2021-2022 | |
| Stryker Corporation | $40.83 | 2025 | Flowtriever |
| Tempus Ai, INC | $38.47 | 2024 | |
| Grifols USA, LLC | $37.99 | 2022-2023 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $32.27 | 2022-2025 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $26.10 | 2021 | |
| Neurocrine Biosciences, INC. | $25.53 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.12 | 2025 | Recorlev |
| Allergan, INC. | $19.93 | 2021 | |
| Hologic Sales and Service, LLC | $18.40 | 2021 | |
| Astellas Pharma US INC | $17.93 | 2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $17.88 | 2022 | |
| Dexcom, INC. | $16.72 | 2021 | |
| Tris Pharma INC | $16.31 | 2025 | Dyanavel Xr |
| Ardelyx, INC. | $16.25 | 2025 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $15.33 | 2025 | |
| Insulet Corporation | $12.68 | 2021 | |
| Sanofi Pasteur INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.